We are live on ! Find out more
JJIJ

Johnson & Johnson Innovation - JJDC Portfolio holdings

AUM $978M
1-Year Est. Return 102.17%
This Fund
S&P 500
This Quarter Est. Return
+43.07%
1 Year Est. Return
+102.17%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$509M
AUM Growth
+$325M
Cap. Flow
+$228M
Cap. Flow %
44.84%
Top 10 Hldgs %
99.65%
Holding
15
New
3
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$101M
2
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$63.9M
3
LEGN icon
Legend Biotech
LEGN
+$63.6M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
2 Technology 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
1
Arrowhead Research
ARWR
$11.8B
$141M 27.67%
3,260,869
– –
FATE icon
2
Fate Therapeutics
FATE
$273M
$116M 22.77%
+3,379,064
New +$101M
LEGN icon
3
Legend Biotech
LEGN
$3.67B
$69.3M 13.62%
+1,629,173
New +$63.6M
FUSN
4
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$64.1M 12.6%
+3,670,516
New +$63.9M
PTGX icon
5
Protagonist Therapeutics
PTGX
$8.71B
$43.3M 8.5%
2,449,183
– –
MGTX icon
6
MeiraGTx Holdings
MGTX
$1.1B
$36.3M 7.13%
2,898,550
– –
PRVB
7
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$15.9M 3.12%
1,124,973
– –
PHGE icon
8
BiomX
PHGE
$1.91M
$11.8M 2.31%
11,228
– –
PHAS
9
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$7.39M 1.45%
1,607,044
– –
ALDX icon
10
Aldeyra Therapeutics
ALDX
$94.7M
$2.48M 0.49%
594,834
– –
CSLT
11
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$673K 0.13%
811,295
– –
GYRE icon
12
Gyre Therapeutics
GYRE
$666M
$393K 0.08%
8,927
– –
GNCA
13
DELISTED
Genocea Biosciences, Inc.
GNCA
$331K 0.07%
143,964
– –
SENS icon
14
Senseonics Holdings Inc
SENS
$258M
$205K 0.04%
26,282
– –
TCON
15
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$165K 0.03%
4,200
– –

Similar funds

NNP
Nachman Norwood & Parrott Greenville, South Carolina $984M AUM 33.8% 1-Year Est. Return
BAWC
Black-and-white Capital Los Angeles, California $967M AUM 94.03% 1-Year Est. Return
RP
RR Partners New York $929M AUM 110.28% 1-Year Est. Return
NIA
Northstar Investment Advisors Denver, Colorado $755M AUM 37.8% 1-Year Est. Return
SCM
Snow Capital Management Sewickley, Pennsylvania $703M AUM 76.26% 1-Year Est. Return
EMG
Ellington Management Group Old Greenwich, Connecticut $676M AUM 23.65% 1-Year Est. Return
APA
Allegiant Private Advisors Sarasota, Florida $618M AUM
HFA
Hoover Financial Advisors Malvern, Pennsylvania $562M AUM 37.9% 1-Year Est. Return

Johnson & Johnson Innovation - JJDC's Q2 2020 Portfolio in Review

As of Q2 2020, Johnson & Johnson Innovation - JJDC held 15 positions worth $509M, up 177% from $184M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Johnson & Johnson Innovation - JJDC deployed $228M of net new capital in Q2 2020, opening 3 new positions. Its largest new stake was Fate Therapeutics: 3,379,064 shares worth $116M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology.

  • Johnson & Johnson Innovation - JJDC's largest Q2 2020 buy was Fate Therapeutics: 3,379,064 shares worth $116M.
  • Johnson & Johnson Innovation - JJDC's ten largest holdings make up 100% of its $509M portfolio in Q2 2020.
  • Johnson & Johnson Innovation - JJDC opened 3 new positions and closed 0 in Q2 2020.
  • Johnson & Johnson Innovation - JJDC's portfolio value rose 177% quarter-over-quarter to $509M.

Based on Johnson & Johnson Innovation - JJDC's 13F filing for Q2 2020, filed 12 Aug 2020.